C
넥스트바이오메디컬
389650KOSDAQ의료용 기기 제조업48.6 / 100
Reference Date: 2026-04-13
Financial Score15.0 / 40
News Sentiment14.6 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 7.8% over the past month, and news sentiment is positive.
Company InformationBased on 2025 Annual Report
Business Overview
NextBioMedical is a biopharma company specializing in drug delivery systems, biocompatible medical devices, and oncology treatments. It focuses on developing pharmaceutical-medical device convergence products, particularly drug-eluting beads for liver cancer therapy and interventional radiology technologies.
Number of Employees
81people
Average Salary
45.6M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 26.524.0Point
PBR
11.36Industry Average 1.700.0Point
6.7x industry avg (risky)
ROE
-0.67Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
6.47Industry Average 10.955.0Point
Lower than industry avg (good)
Trend 2024~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲72.7% (1-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲79.9% (1-year basis)
ROE Trend
0.0 / 4
Detailed News Sentiment
7 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80
- Positive나 홀로 K바이오 한계...“글로벌 거인에 얹혀라” 주장 ‘이 남자’
넥스트바이오메디컬이 글로벌 대형 기업의 영업·유통망을 활용하는 전략으로 의료기기 산업에서 새로운 성공 방정식을 모색하고 있습니다.
- Positive넥스트바이오메디컬, 2025년 매출 165억 전년대비 73%↑
넥스트바이오메디컬이 2025년 매출액이 전년 대비 73% 성장하고 영업손실 폭을 크게 줄이며 수익성 개선 흐름을 보였습니다.
Detailed Momentum
52-week position5.0Point
52w mid range (46%)
Current 66,600Won52-week high 98,00052-week low 39,000
1-month return1.0Point
1m -7.76% (falling)
Volume trend3.0Point
Volume flat
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral[기재정정]사업보고서 (2025.12)2026-03-20
- Neutral사업보고서 (2025.12)2026-03-19
- Neutral감사보고서제출2026-03-19